An interventional study of Augmented Depression Therapy (ADepT) in Depression / Major Depressive Disorder, sponsored by Ohio State University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Ohio State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Depression by Ohio State University — 5 open to participants now, 5 under way, none of them phase 3. Depression · Ohio State University.
Among the 17 studies in Depression by Ohio State University, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2027, is one of 14 with no phase, and was the 16th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →5 of the 17 studies in Depression by Ohio State University are open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 21–65
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 14–17
Ohio State University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 40 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 120 across the 16 interventional studies, 456 across the 1 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Depression by Ohio State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works. ADepT is a type of therapy that builds wellbeing and is being provided to you as standard of care.
ADepT treatment consists of 15 therapy sessions (typically provided weekly) with each session lasting around 60 minutes. Following these sessions, you can receive five optional booster sessions over the next 12 months with each of these lasting around 60 minutes. Ultimately, the timing and duration of these sessions will be determined between you and your provider and scheduled accordingly.
As part of this study you will be randomized (randomly assigned) to different research assessment lengths before the start of treatment and then will complete assessments for the 12 months following the end of the weekly portion of ADepT treatment. The length of your participation will be between 70 weeks to 82 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baseline assessments will be made weekly for 3 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
Baseline assessments will be made weekly for 4 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
Baseline assessments will be made weekly for 5 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
Baseline assessments will be made weekly for 6 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
Baseline assessments will be made weekly for 7 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
Baseline assessments will be made weekly for 8 weeks, followed by a standard course of ADepT.
Behavioral: Augmented Depression Therapy (ADepT)
ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Acceptability
Patient ratings of treatment acceptability
Time frame: From enrollment to the end of treatment at 82 weeks
Attrition
Patient attendance records
Time frame: From enrollment to the end of treatment at 82 weeks.
Adverse Events
Self-reported adverse events
Time frame: From enrollment to the end of treatment at 82 weeks.
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a clinician-administered, 10-item assessment tool used to measure the severity of depressive symptoms and monitor changes in depression over time. Min=0, Max=60, higher scores indicate worse depression.
Time frame: From enrollment to the end of treatment at 82 weeks.
Patient Health Questionnaire - 9 Item Version (PHQ-9)
The PHQ-9 is a 9-item self-report measure of depression severity. Min=0, Max=27, higher scores indicate worse depression.
Time frame: From enrollment to the end of treatment at 82 weeks.
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
The WEMWBS is a 14-item self-report questionnaire designed to measure positive mental wellbeing, including emotional, psychological, and social functioning. Min=14, Max=70, higher scores indicate higher levels of wellbeing.
Time frame: From enrollment to the end of treatment at 82 weeks.
Plan to share: Yes — Only IRB approved personnel will have access to identifiable data. De-identified data may be shared with other research groups examining similar questions or as a requirement for publication in certain journals.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.